For each question, please circle the best response on the answer key provided on pages S43/S44. A statement of credit will be mailed to those who successfully complete the examination with a minimum score of 75%.
1. In the late 1980s, the number of new cases of hepatitis C virus (HCV) infections occurring annually in the United States was
2. By 1998, HCV incidence in the United States was
3. The overall prevalence of HCV infection in the general US population in 1998 was estimated to be
4. Between 1990 and 2015, the number of patients diagnosed with HCV in the United States is projected to
5. The major risk factor for HCV infections in the United States today is
6. Of patients infected with HCV who go on to develop chronic hepatitis, the percentage of patients who will eventually develop cirrhosis is approximately
7. The rate of progression to cirrhosis in patients with chronic HCV infection is influenced by
8. The most accurate measure of HCV disease severity is
9. Patients with HCV genotype 1 have a higher response rate to antiviral therapy than patients with genotypes 2 and 3.
10. In all patients infected with HCV who receive a combination of interferon and ribavirin, the overall sustained virologic response rate is approximately
11. The enhanced virologic response rate of the pegylated interferons in HCV infections is related to
12. There is evidence that HCV cirrhosis can actually be reversed by HCV antiviral therapy.
13. In large clinical trials of patients treated with interferon, the incidence of fatigue, headache, and myalgia was approximately
14. The interferon/ribavirin dosing strategy that has been shown to improve sustained virologic response in the most difficult-totreat genotype of HCV is
15. Absolute contraindications to interferon alfa treatment include
16. The most common dosing regimen for pegylated interferon (Peg IFN) and ribavirin (RI antiviral therapy today is
17. Dose reduction is a common strategy for reducing the impact of the common ribavirin-induced side effect of
18. Pharmacists can assure patients that there is absolutely no risk of intrahousehold HCV transmission with the sharing of common household items such as razors or toothbrushes.
19. The most recent Consensus Statement from the National Institutes of Health states that antiviral therapy is absolutely NOT recommended for HCV-infected patients with
20. Nonresponders to interferon plus ribavirin therapy are candidates for further treatment.